ATE273711T1 - Verwendung von niedermolekularem heparin zur behandlung und/oder prophylaxe motoneuronaler krankheiten - Google Patents

Verwendung von niedermolekularem heparin zur behandlung und/oder prophylaxe motoneuronaler krankheiten

Info

Publication number
ATE273711T1
ATE273711T1 AT99958308T AT99958308T ATE273711T1 AT E273711 T1 ATE273711 T1 AT E273711T1 AT 99958308 T AT99958308 T AT 99958308T AT 99958308 T AT99958308 T AT 99958308T AT E273711 T1 ATE273711 T1 AT E273711T1
Authority
AT
Austria
Prior art keywords
low molecular
prophylaxis
treatment
molecular heparin
diseases
Prior art date
Application number
AT99958308T
Other languages
English (en)
Inventor
Jean-Marie Stutzmann
Andre Uzan
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Application granted granted Critical
Publication of ATE273711T1 publication Critical patent/ATE273711T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • External Artificial Organs (AREA)
AT99958308T 1998-12-17 1999-12-13 Verwendung von niedermolekularem heparin zur behandlung und/oder prophylaxe motoneuronaler krankheiten ATE273711T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9815919A FR2787329B1 (fr) 1998-12-17 1998-12-17 Nouvelle application therapeutique des heparines de bas poids moleculaire
PCT/FR1999/003109 WO2000035462A1 (fr) 1998-12-17 1999-12-13 Nouvelle application therapeutique des heparines de bas poids moleculaire

Publications (1)

Publication Number Publication Date
ATE273711T1 true ATE273711T1 (de) 2004-09-15

Family

ID=9534065

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99958308T ATE273711T1 (de) 1998-12-17 1999-12-13 Verwendung von niedermolekularem heparin zur behandlung und/oder prophylaxe motoneuronaler krankheiten

Country Status (15)

Country Link
US (4) US20020040013A1 (de)
EP (1) EP1140119B1 (de)
JP (1) JP2002532431A (de)
AT (1) ATE273711T1 (de)
AU (1) AU1569700A (de)
CA (1) CA2354762C (de)
DE (1) DE69919578T2 (de)
DK (1) DK1140119T3 (de)
ES (1) ES2222748T3 (de)
FR (1) FR2787329B1 (de)
IL (2) IL143279A0 (de)
NO (1) NO20012849L (de)
PT (1) PT1140119E (de)
SI (1) SI1140119T1 (de)
WO (1) WO2000035462A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4897991B2 (ja) * 1999-07-23 2012-03-14 ラボラトリオス ファルマセウティコス ロビ ソシエダッド アノニマ 超低分子量ヘパリン組成物
US7511026B2 (en) 2003-03-25 2009-03-31 Seikagaku Corporation Therapeutic agent for nerve damage
AU2004224779A1 (en) * 2003-03-28 2004-10-07 Laboratoires Serono Sa Use of clusterin for the treatment and/or prevention of peripheral neurological diseases
FR3000746A1 (fr) 2013-01-04 2014-07-11 Centre Nat Rech Scient Peptide pour son utilisation dans le traitement des neuronopathies motrices
RU2639574C2 (ru) * 2016-05-23 2017-12-21 Алексей Георгиевич Александров Способ получения низкомолекулярного гепарина

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4608365A (en) * 1984-03-30 1986-08-26 University Of Southern California Treatment of neurologic functions
JPH04507234A (ja) * 1988-04-22 1992-12-17 ベイラー・カレッジ・オブ・メディスン 筋萎縮性側索硬化症の治療用組成物の製造方法
EP0493533A4 (en) * 1989-10-27 1992-10-28 Case Western Reserve University Inhibition of cell growth by keratan sulfate, chondroitin sulfate, dermatan sulfate and other glycans
US6258341B1 (en) * 1995-04-14 2001-07-10 Inhale Therapeutic Systems, Inc. Stable glassy state powder formulations
FR2740686B1 (fr) * 1995-11-03 1998-01-16 Sanofi Sa Formulation pharmaceutique lyophilisee stable
US6491965B1 (en) * 1995-11-30 2002-12-10 Hamilton Civic Hospitals Research Development, Inc. Medical device comprising glycosaminoglycan-antithrombin III/heparin cofactor II conjugates
FR2763849B1 (fr) * 1997-05-28 2000-09-15 Rhone Poulenc Rorer Sa Utilisation des heparines de bas poids moleculaire pour la prevention et le traitement des oedemes cerebraux
US6608042B2 (en) * 2000-03-28 2003-08-19 Aventis Pharma, S.A. Pharmaceutical compositions containing oligosaccharides, the novel oligosaccharides and preparation thereof

Also Published As

Publication number Publication date
IL143279A0 (en) 2002-04-21
JP2002532431A (ja) 2002-10-02
DE69919578T2 (de) 2005-07-14
EP1140119B1 (de) 2004-08-18
CA2354762C (fr) 2010-02-09
SI1140119T1 (en) 2004-10-31
NO20012849D0 (no) 2001-06-08
FR2787329A1 (fr) 2000-06-23
NO20012849L (no) 2001-06-08
EP1140119A1 (de) 2001-10-10
US20040038938A1 (en) 2004-02-26
US20030236222A1 (en) 2003-12-25
PT1140119E (pt) 2004-11-30
IL143279A (en) 2006-12-10
ES2222748T3 (es) 2005-02-01
DK1140119T3 (da) 2004-12-20
WO2000035462A1 (fr) 2000-06-22
DE69919578D1 (de) 2004-09-23
US20060100175A1 (en) 2006-05-11
FR2787329B1 (fr) 2001-02-09
AU1569700A (en) 2000-07-03
US20020040013A1 (en) 2002-04-04
CA2354762A1 (fr) 2000-06-22

Similar Documents

Publication Publication Date Title
ATE555803T1 (de) Verwendung von osteopontin zur behandlung und/oder vorbeugung von neurologischen erkrankungen
DE69733329D1 (de) Verwendung von Taurin zur Behandlung oder Vorbeugung von ischämischen Verletzungen
UY26249A1 (es) Moléculas pequenas útiles en el tratamiento de las enfermedades inflamatorias ley 17164 art. 127
DE69921156D1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
ATE235495T1 (de) 8-arylalkyl- und 8-arylheteroalkyl-5, 11-dihydro- 6h-dipyrido-(3,2-b:2', 3'-e)(1,4)diazepine und ihre verwendung zur vorbeugung oder behandlung von hiv-infektion
DE69916629D1 (de) Taurolidin und/oder taurultam zur behandlung von infektiösen ulcera oder gastritis
EP1043983A4 (de) Tetracycline und/oder tetracyclinderivate zur behandlung und prophylaxe von cerebrovascularen krankheiten des nervensystems
DE59707519D1 (de) Verwendung von 1-hydroxy-2-pyridonen zur behandlung von hautinfektionen
DE69638281D1 (de) Anti-Interleukin-9 Antikörper oder Anti-Interleukin-9 Rezeptor Antikörper zur Behandlung von bronchialem Hyperreaktionsvermögen
ATE273711T1 (de) Verwendung von niedermolekularem heparin zur behandlung und/oder prophylaxe motoneuronaler krankheiten
ATE359808T1 (de) Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma
ATE246924T1 (de) Neue therapeutische verwendung von nicergoline
DE69701458D1 (de) Verwendung von buckminsterfulleren zur behandlung neurotoxischer verletzungen
DE60213365D1 (de) Verwendung von mglur5 antagonisten zur behandlung von pruritischen zuständen
ATE225181T1 (de) Verwendung von heparinen niedrigeren molekulargewichtes zur behandlung von hirnödemen
DE69936779D1 (de) Verwendung von ngali nussöl zur behandlung/linderung der arthritisschmerzen und anderer ähnlichen störungen
DE50200626D1 (de) Topische verwendung von ätherischen ölen zur behandlung von wundheilungsstörungen
ATE275949T1 (de) Verwendung von diminazen-di-aceturat und/oder pentamidin zur behandlung von malaria
DE69810724D1 (de) Verwendung von Protein C Inhibitor zur Behandlung disseminierter intravasaler Gerinnung (DIC)
DE69712287D1 (de) Verwendung von Sulbutiamin zur Behandlung von psychomotorischen oder psychointellektuellen Beschwerden
ATA96097A (de) Verwendung von queller zur behandlung oder prophylaxe von jodmangelerscheinungen
ATE247467T1 (de) Neue therapeutische verwendung von 1,6-dimethyl- 8beta-hydroxymethyl-10alpha-methoxyergolin
ATE209910T1 (de) Verwendung von 6,7-substituierter 2- aminotetraline zur behandlung von zytokin- vermittleten entzündungszuständen
DE50012015D1 (de) Mittel zur prävention und/oder behandlung einer gewebeveränderung mesenchymalen ursprungs
DE69822628D1 (de) Zur vorbeugung oder behandlung von östrogenabhängigen krankheiten nützliche pyrrolo[2.1.5-cd]indolizin-derivate

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1140119

Country of ref document: EP

REN Ceased due to non-payment of the annual fee